Skip to main content

Advertisement

Table 2 Evaluation of VEGF binding affinity in aflibercept and ziv-aflibercept samples under different storage conditions

From: Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding

  VEGF binding affinity (µg/mL)
Aflibercept Ziv-aflibercept
Expected mass 0.200 0.125
Pre-assay 0.208 ± 0.041 0.136 ± 0.004
14 days/4 °C 0.185 ± 0.036 0.121 ± 0.005
14 days/− 8 °C 0.196 ± 0.010 0.130 ± 0.006
28 days/4 °C 0.175 ± 0.019 0.129 ± 0.013
28 days/− 8 °C 0.147 ± 0.014 0.134 ± 0.003
  1. Samples of aflibercept and ziv-aflibercept were added to ELISA plates, after coating the plates with anti-VEGF capture antibody and after binding the recombinant molecule of human VEGF (both R&D components). The aflibercept’s or ziv-aflibercept’s anti-VEGF able to bind to the recombinant VEGF was detected by HRP-conjugated anti-human IgG and H2O2-OPD substrate, and quantification (µg/mL) was based on a standard curve performed with both drugs. The drugs were initially diluted in saline (1:200,000 for aflibercept; 1:100,000 for ziv-aflibercept). Statistical analysis was performed comparing the samples to the moment condition of each drug
  2. The data are expressed as the mean ± SD